MedPlus subsidiary Optival Health received two drug license suspension orders from state authorities in Andhra Pradesh and Odisha.
The suspensions are for seven days and two days, potentially causing revenue losses of ₹5.85 lakh and ₹0.96 lakh respectively.
The disclosure is made pursuant to SEBI Listing Regulations and circulars dated July 2023 and December 2024.
The orders cite violations under Rule 65 of the Drugs and Cosmetics Act, 1940 and its 1945 Rules.